Nanobiotix (NBTX) Expected to Announce Quarterly Earnings on Wednesday

Nanobiotix (NASDAQ:NBTX) is anticipated to announce its H2 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of $0.2012 per share and revenue of $41.9520 million for the quarter. Parties may review the information on the company’s upcoming H2 2025 earning report for the latest details on the call scheduled for Thursday, April 2, 2026 at 11:40 AM ET.

Nanobiotix Trading Down 4.2%

NASDAQ:NBTX opened at $29.27 on Wednesday. Nanobiotix has a twelve month low of $2.99 and a twelve month high of $41.89. The stock has a fifty day simple moving average of $26.67 and a 200-day simple moving average of $22.37.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a report on Tuesday, November 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. Finally, Guggenheim lifted their target price on Nanobiotix from $8.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $20.00.

Institutional Investors Weigh In On Nanobiotix

Several large investors have recently modified their holdings of NBTX. Royal Bank of Canada lifted its position in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after purchasing an additional 2,500 shares during the period. Marshall Wace LLP purchased a new position in Nanobiotix during the fourth quarter valued at approximately $220,000. Finally, Millennium Management LLC purchased a new position in Nanobiotix during the fourth quarter valued at approximately $390,000. Institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.